259 related articles for article (PubMed ID: 36575406)
41. Efficacies of atovaquone, pentamidine, and trimethoprim/sulfamethoxazole for the prevention of Pneumocystis jirovecii pneumonia in patients with connective tissue diseases.
Kitazawa T; Seo K; Yoshino Y; Asako K; Kikuchi H; Kono H; Ota Y
J Infect Chemother; 2019 May; 25(5):351-354. PubMed ID: 30711257
[TBL] [Abstract][Full Text] [Related]
42. Low-Dose TMP-SMX in the Treatment of
Butler-Laporte G; Smyth E; Amar-Zifkin A; Cheng MP; McDonald EG; Lee TC
Open Forum Infect Dis; 2020 May; 7(5):ofaa112. PubMed ID: 32391402
[TBL] [Abstract][Full Text] [Related]
43. Low-Dose TMP-SMX for
Chen JK; Guerci J; Corbo H; Richmond M; Martinez M
J Pediatr Pharmacol Ther; 2023; 28(2):123-128. PubMed ID: 37139252
[TBL] [Abstract][Full Text] [Related]
44. Pneumocystis jirovecii pneumonia in systemic autoimmune rheumatic disease: A case-control study.
Tadros S; Teichtahl AJ; Ciciriello S; Wicks IP
Semin Arthritis Rheum; 2017 Jun; 46(6):804-809. PubMed ID: 27814896
[TBL] [Abstract][Full Text] [Related]
45. The risk factor analysis and treatment experience in pneumocystis jirovecii pneumonia after kidney transplantation.
Yang P; Zhu X; Liang W; Cai R
Mycoses; 2021 May; 64(5):495-502. PubMed ID: 33368732
[TBL] [Abstract][Full Text] [Related]
46. Anidulafungin as an alternative treatment for Pneumocystis jirovecii pneumonia in patients who cannot tolerate trimethoprim/sulfamethoxazole.
Chen PY; Yu CJ; Chien JY; Hsueh PR
Int J Antimicrob Agents; 2020 Jan; 55(1):105820. PubMed ID: 31622654
[TBL] [Abstract][Full Text] [Related]
47. Lessons from Multiple Infections Such as Lymphoma Complicated with Pneumocystis Infection: A Case Report.
Wang H; Lang Y; Cai X; Gao L; Yang S; Jin J
Infect Drug Resist; 2024; 17():1583-1588. PubMed ID: 38681899
[TBL] [Abstract][Full Text] [Related]
48. Treatment of Pneumocystis pneumonia with intermediate-dose and step-down to low-dose trimethoprim-sulfamethoxazole: lessons from an observational cohort study.
Creemers-Schild D; Kroon FP; Kuijper EJ; de Boer MG
Infection; 2016 Jun; 44(3):291-9. PubMed ID: 26471512
[TBL] [Abstract][Full Text] [Related]
49. Clinical descriptive analysis of severe
Xie D; Xu W; You J; Yuan X; Li M; Bi X; Zhang K; Li H; Xian Y
Bioengineered; 2021 Dec; 12(1):1264-1272. PubMed ID: 33896387
[No Abstract] [Full Text] [Related]
50. Good outcome with trimethoprim 10 mg/kg/day-sulfamethoxazole 50 mg/kg/day for Pneumocystis jirovecii pneumonia in HIV infected patients.
Thomas M; Rupali P; Woodhouse A; Ellis-Pegler R
Scand J Infect Dis; 2009; 41(11-12):862-8. PubMed ID: 19922070
[TBL] [Abstract][Full Text] [Related]
51. Safety and efficacy of prophylaxis for Pneumocystis jirovecii pneumonia involving trimethoprim-sulfamethoxazole dose reduction in kidney transplantation.
Prasad GVR; Beckley J; Mathur M; Gunasekaran M; Nash MM; Rapi L; Huang M; Zaltzman JS
BMC Infect Dis; 2019 Apr; 19(1):311. PubMed ID: 30953458
[TBL] [Abstract][Full Text] [Related]
52. Prophylactic effect of trimethoprim-sulfamethoxazole for pneumocystis pneumonia in patients with rheumatic diseases exposed to prolonged high-dose glucocorticoids.
Park JW; Curtis JR; Moon J; Song YW; Kim S; Lee EB
Ann Rheum Dis; 2018 May; 77(5):644-649. PubMed ID: 29092853
[TBL] [Abstract][Full Text] [Related]
53. Clinical Characteristics and Risk Factors for Pneumocystis Jirovecii Pneumonia during Immunosuppressive Treatment in Patients with Ulcerative Colitis: A Retrospective Study.
Kojima K; Sato T; Uchino M; Yokoyama Y; Takagawa T; Ohda Y; Hida N; Watanabe K; Hori K; Miwa H; Ikeuchi H; Nakamura S; Shimizu M
J Gastrointestin Liver Dis; 2020 Jun; 29(2):167-173. PubMed ID: 32530983
[TBL] [Abstract][Full Text] [Related]
54. Trimethoprim-Sulfamethoxazole-associated early neutropenia in Mexican adults living with HIV: A cohort study.
Jacobo-Vargas TB; Báez-Saldaña R; Cruz-Hervert LP; Fortoul TI; Ahumada-Topete VH; Rodríguez-Ganén O; Vega-Barrientos RS
PLoS One; 2023; 18(5):e0285541. PubMed ID: 37167312
[TBL] [Abstract][Full Text] [Related]
55. Pneumocystis jirovecii pneumonia in autoimmune rheumatic diseases: a nationwide population-based study.
Hsu HC; Chang YS; Hou TY; Chen LF; Hu LF; Lin TM; Chiou CS; Tsai KL; Lin SH; Kuo PI; Chen WS; Lin YC; Chen JH; Chang CC
Clin Rheumatol; 2021 Sep; 40(9):3755-3763. PubMed ID: 33646447
[TBL] [Abstract][Full Text] [Related]
56. Reversible myoclonus, asterixis, and tremor associated with high dose trimethoprim-sulfamethoxazole: a case report.
Gray DA; Foo D
J Spinal Cord Med; 2016; 39(1):115-7. PubMed ID: 26111222
[TBL] [Abstract][Full Text] [Related]
57. The role of CD4 cell count as discriminatory measure to guide chemoprophylaxis against Pneumocystis jirovecii pneumonia in human immunodeficiency virus-negative immunocompromised patients: A systematic review.
Messiaen PE; Cuyx S; Dejagere T; van der Hilst JC
Transpl Infect Dis; 2017 Apr; 19(2):. PubMed ID: 28035717
[TBL] [Abstract][Full Text] [Related]
58. Clinical Characteristics and Epidemiological Analysis of Pneumocystis Jirovecii Pneumonia Infection in Kidney Transplant Patients with Trimethoprim-Sulfamethoxazole Dose Reduction Prophylaxis Strategy.
Shan W; Wang L; Qin J; Peng W; Ma K
Infect Drug Resist; 2024; 17():2299-2306. PubMed ID: 38868399
[TBL] [Abstract][Full Text] [Related]
59. Clinical-epidemiological characteristics of Pneumocystis jirovecii pneumonia in a tertiary hospital in Spain.
Martín Pedraz L; Carazo Gallego B; Moreno Pérez D
An Pediatr (Engl Ed); 2021 Jul; 95(1):4-10. PubMed ID: 34154986
[TBL] [Abstract][Full Text] [Related]
60. A Four-Center Retrospective Study of the Efficacy and Toxicity of Low-Dose Trimethoprim-Sulfamethoxazole for the Treatment of Pneumocystis Pneumonia in Patients without HIV Infection.
Kosaka M; Ushiki A; Ikuyama Y; Hirai K; Matsuo A; Hachiya T; Hanaoka M
Antimicrob Agents Chemother; 2017 Dec; 61(12):. PubMed ID: 28893787
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
